InsidersTradesSigma
Follow the Lixte Biotechnology Holdings, INC. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, Lixte Biotechnology Holdings, INC. has published 21 reports. Market capitalisation: €125.4m. The latest transaction was filed on 17 April 2026 (Attribution). Among the most active insiders: FORMAN ERIC. Every trade is openly available.
21
Insider Decl.
n/a
Thresholds
€147,061
13 ops.
Buy Volume
n/a
n/a
Sell Volume
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 April 2026
Declarations21 total
25,000 sharesCommon StockSEC:0001493152-26-017856:0
25,000 sharesCommon StockSEC:0001493152-26-017852:0
25,000 sharesCommon StockSEC:0001493152-26-017853:0
25,000 sharesCommon StockSEC:0001493152-26-017854:0
350,000 sharesCommon StockSEC:0001493152-26-017855:0
50,000 sharesCommon StockSEC:0001493152-26-017857:0
4,473 shares@ US$2.2916.4% of flowCommon StockSEC:0001493152-23-036424:0
Canonical exit: 31 Dec 2023 (T+90)
10,000 shares@ US$2.8034.6% of flowCommon StockSEC:0001493152-23-036422:0
Canonical exit: 1 Jan 2024 (T+90)
4,473 shares@ US$2.2916.4% of flowCommon StockSEC:0001493152-23-035712:0
Canonical exit: 31 Dec 2023 (T+90)
10,000 shares@ US$0.495.9% of flowCommon StockSEC:0001493152-23-000449:0
Canonical exit: 30 Mar 2023 (T+90)
10,000 shares@ US$4.9059.5% of flowCommon StockSEC:0001493152-23-000255:0
Canonical exit: 30 Mar 2023 (T+90)
15,000 shares@ US$0.5112.1% of flowCommon StockSEC:0001493152-22-035794:0
Canonical exit: 15 Mar 2023 (T+90)
10,000 shares@ US$0.6063.2% of flowCommon StockSEC:0001493152-22-035281:0
Canonical exit: 9 Mar 2023 (T+90)
10,000 shares@ US$0.619.8% of flowCommon StockSEC:0001493152-22-035280:0
Canonical exit: 12 Mar 2023 (T+90)
1,457 shares@ US$0.568.8% of flowCommon StockSEC:0001493152-22-033573:0
Canonical exit: 19 Feb 2023 (T+90)
2,400 shares@ US$0.57100.0% of flowCommon StockSEC:0001493152-22-033261:0
Canonical exit: 19 Feb 2023 (T+90)
4,852 shares@ US$0.539828.0% of flowCommon StockSEC:0001493152-22-033084:0
Canonical exit: 15 Feb 2023 (T+90)
52,500 shares@ US$0.5345.3% of flowCommon StockSEC:0001493152-22-032564:0
Canonical exit: 12 Feb 2023 (T+90)
1,333,333 shares0Common StockSEC:0001493152-22-009303:0
34,000 sharesCommon stockSEC:0001493152-16-007181:0
2,500 sharesCommon stockSEC:0001493152-16-007181:1
Canonical exit: 4 May 2016 (T+90)
21 of 21 declarations
Acerca de Lixte Biotechnology Holdings, INC.
Lixte Biotechnology Holdings, INC. es una empresa centrada en el desarrollo de tratamientos contra el cáncer. Se especializa en el descubrimiento de nuevas terapias y tecnologías en el sector de la biotecnología.